BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lopiano L, Modugno N, Marano P, Sensi M, Meco G, Solla P, Gusmaroli G, Tamma F, Mancini F, Quatrale R, Zangaglia R, Bentivoglio A, Eleopra R, Gualberti G, Melzi G, Antonini A. Motor and non-motor outcomes in patients with advanced Parkinson's disease treated with levodopa/carbidopa intestinal gel: final results of the GREENFIELD observational study. J Neurol 2019;266:2164-76. [PMID: 31134377 DOI: 10.1007/s00415-019-09337-6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 27] [Article Influence: 6.3] [Reference Citation Analysis]
Number Citing Articles
1 Rus T, Premzl M, Križnar NZ, Kramberger MG, Rajnar R, Ocepek L, Pirtošek Z, Trošt M. Adverse effects of levodopa/carbidopa intrajejunal gel treatment: A single-center long-term follow-up study. Acta Neurol Scand 2022. [PMID: 35903042 DOI: 10.1111/ane.13675] [Reference Citation Analysis]
2 Garrì F, Russo FP, Carrer T, Weis L, Pistonesi F, Mainardi M, Sandre M, Savarino E, Farinati F, Del Sorbo F, Soliveri P, Calandrella D, Biundo R, Carecchio M, Zecchinelli AL, Pezzoli G, Antonini A. Long-term safety, discontinuation and mortality in an Italian cohort with advanced Parkinson's disease on levodopa/carbidopa intestinal gel infusion. J Neurol 2022. [PMID: 35876875 DOI: 10.1007/s00415-022-11269-7] [Reference Citation Analysis]
3 Adebayo OG, Asiwe JN, Ben-Azu B, Aduema W, Onyeleonu I, Akpotu AE, Wopara I, Kolawole TA, Umoren EB, Igbokwe V, Buduburisi BR, Onwuka FC, Brown PI. Ginkgo biloba protects striatal neurodegeneration and gut phagoinflammatory damage in rotenone-induced mice model of Parkinson's disease: Role of executioner caspase-3/Nrf2/ARE signaling. J Food Biochem 2022;:e14253. [PMID: 35608987 DOI: 10.1111/jfbc.14253] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Simoni S, Nigro P, Filidei M, Cappelletti G, Paolini Paoletti F, Castellani D, Gaggiotti M, Parnetti L, Tambasco N. PEG-J replacement for duodenal levodopa infusion in Parkinson’s disease patients: a retrospective study. BMC Neurol 2022;22. [DOI: 10.1186/s12883-021-02546-5] [Reference Citation Analysis]
5 Simu MA, Jianu DC, Dulamea AO, Constantin VA, Popescu D, Parra JC, Szász JA. Advanced Parkinson's Disease Treatment Simplification and Long-Term Outcomes with Levodopa Carbidopa Intestinal Gel: COSMOS Romanian Subanalysis. Brain Sci 2021;11:1566. [PMID: 34942868 DOI: 10.3390/brainsci11121566] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Standaert DG, Aldred J, Anca-Herschkovitsch M, Bourgeois P, Cubo E, Davis TL, Iansek R, Kovács N, Pontieri FE, Siddiqui MS, Simu M, Bergmann L, Kukreja P, Robieson WZ, Chaudhuri KR. DUOGLOBE: One-Year Outcomes in a Real-World Study of Levodopa Carbidopa Intestinal Gel for Parkinson's Disease. Mov Disord Clin Pract 2021;8:1061-74. [PMID: 34631942 DOI: 10.1002/mdc3.13239] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
7 Hutny M, Hofman J, Klimkowicz-Mrowiec A, Gorzkowska A. Current Knowledge on the Background, Pathophysiology and Treatment of Levodopa-Induced Dyskinesia-Literature Review. J Clin Med 2021;10:4377. [PMID: 34640395 DOI: 10.3390/jcm10194377] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
8 Freire-Alvarez E, Kurča E, Lopez Manzanares L, Pekkonen E, Spanaki C, Vanni P, Liu Y, Sánchez-Soliño O, Barbato LM. Levodopa-Carbidopa Intestinal Gel Reduces Dyskinesia in Parkinson's Disease in a Randomized Trial. Mov Disord 2021. [PMID: 34236101 DOI: 10.1002/mds.28703] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
9 Baig F, Boca M, Mooney L, Cheminais L, Selikhova M, Rolinski M, Szewczyk-Krolikowski K, Collin N, Whone A. Per-oral image guided gastrojejunostomy insertion for levodopa-carbidopa intestinal gel in Parkinson's disease is safe and may be advantageous. Parkinsonism Relat Disord 2021;89:34-7. [PMID: 34218045 DOI: 10.1016/j.parkreldis.2021.06.022] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Szász JA, Constantin VA, Orbán-Kis K, Bancu LA, Ciorba M, Mihály I, Nagy EE, Szász RM, Kelemen K, Simu MA, Szatmári S. Management Challenges of Severe, Complex Dyskinesia. Data from a Large Cohort of Patients Treated with Levodopa-Carbidopa Intestinal Gel for Advanced Parkinson's Disease. Brain Sci 2021;11:826. [PMID: 34206596 DOI: 10.3390/brainsci11070826] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
11 Antonini A, Odin P, Pahwa R, Aldred J, Alobaidi A, Jalundhwala YJ, Kukreja P, Bergmann L, Inguva S, Bao Y, Chaudhuri KR. The Long-Term Impact of Levodopa/Carbidopa Intestinal Gel on 'Off'-time in Patients with Advanced Parkinson's Disease: A Systematic Review. Adv Ther 2021;38:2854-90. [PMID: 34018146 DOI: 10.1007/s12325-021-01747-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
12 Salles PA, Mata IF, Fernandez HH. Should we start integrating genetic data in decision-making on device-aided therapies in Parkinson disease? A point of view. Parkinsonism Relat Disord 2021;88:51-7. [PMID: 34119931 DOI: 10.1016/j.parkreldis.2021.05.013] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
13 Fabbrini A, Guerra A. Pathophysiological Mechanisms and Experimental Pharmacotherapy for L-Dopa-Induced Dyskinesia. J Exp Pharmacol 2021;13:469-85. [PMID: 33953618 DOI: 10.2147/JEP.S265282] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
14 Tsunemi T, Oyama G, Saiki S, Hatano T, Fukae J, Shimo Y, Hattori N. Intrajejunal Infusion of Levodopa/Carbidopa for Advanced Parkinson's Disease: A Systematic Review. Mov Disord 2021;36:1759-71. [PMID: 33899262 DOI: 10.1002/mds.28595] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
15 Klietz M, von Eichel H, Schnur T, Staege S, Höglinger GU, Wegner F, Stiel S. One Year Trajectory of Caregiver Burden in Parkinson's Disease and Analysis of Gender-Specific Aspects. Brain Sci 2021;11:295. [PMID: 33652825 DOI: 10.3390/brainsci11030295] [Cited by in Crossref: 2] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
16 Thakkar S, Fung VSC, Merola A, Rollins M, Soileau MJ, Kovács N. 24-Hour Levodopa-Carbidopa Intestinal Gel: Clinical Experience and Practical Recommendations. CNS Drugs 2021;35:137-49. [PMID: 33582982 DOI: 10.1007/s40263-020-00782-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
17 Niemann N, Billnitzer A, Jankovic J. Parkinson's disease and skin. Parkinsonism Relat Disord 2021;82:61-76. [PMID: 33248395 DOI: 10.1016/j.parkreldis.2020.11.017] [Cited by in Crossref: 4] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
18 Paolone G. From the Gut to the Brain and Back: Therapeutic Approaches for the Treatment of Network Dysfunction in Parkinson's Disease. Front Neurol 2020;11:557928. [PMID: 33117258 DOI: 10.3389/fneur.2020.557928] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
19 Aldred J, Anca-Herschkovitsch M, Antonini A, Bajenaru O, Bergmann L, Bourgeois P, Cubo E, Davis TL, Iansek R, Kovács N, Kukreja P, Onuk K, Pontieri FE, Robieson W, Siddiqui MS, Simu M, Standaert DG, Chaudhuri KR. Application of the '5-2-1' screening criteria in advanced Parkinson's disease: interim analysis of DUOGLOBE. Neurodegener Dis Manag 2020;10:309-23. [PMID: 32873195 DOI: 10.2217/nmt-2020-0021] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
20 Ehlers C, Timpka J, Odin P, Honig H. Levodopa infusion in Parkinson's disease: Individual quality of life. Acta Neurol Scand 2020;142:248-54. [PMID: 32383152 DOI: 10.1111/ane.13260] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
21 Prakash N, Simuni T. Infusion Therapies for Parkinson’s Disease. Curr Neurol Neurosci Rep 2020;20. [DOI: 10.1007/s11910-020-01062-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
22 Kamel WA, Al-Hashel JY. LCIG in treatment of non-motor symptoms in advanced Parkinson's disease: Review of literature. Brain Behav 2020;10:e01757. [PMID: 32677345 DOI: 10.1002/brb3.1757] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
23 Ransmayr G. Belastungen in der Betreuung von Parkinson-Patientinnen und - Patienten. Fortschr Neurol Psychiatr 2020;88:567-72. [DOI: 10.1055/a-1120-8567] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
24 Kulisevsky J, Bejr-Kasem H, Martinez-Horta S, Horta-Barba A, Pascual-Sedano B, Campolongo A, Marín-Lahoz J, Aracil-Bolaños I, Pérez-Pérez J, Izquierdo-Barrionuevo C, de Fàbregues O, Puente V, Crespo-Cuevas A, Calopa M, Pagonabarraga J. Subclinical affective and cognitive fluctuations in Parkinson's disease: a randomized double-blind double-dummy study of Oral vs. Intrajejunal Levodopa. J Neurol 2020;267:3400-10. [PMID: 32607644 DOI: 10.1007/s00415-020-10018-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Antonini A, Abbruzzese G, Berardelli A, Modugno N, Stroppa I, Tamma F, Sensi M, Mancini F, Cossu G, Stefani A, Tambasco N, Tessitore A, Fabbrini G, Pontieri FE, Solla P, Bentivoglio AR, Comi C, Minafra B, Riboldazzi G, Melchionda D, Martino T, Lopiano L. The TANDEM investigation: efficacy and tolerability of levodopa-carbidopa intestinal gel in (LCIG) advanced Parkinson's disease patients. J Neural Transm (Vienna) 2020;127:881-91. [PMID: 32212015 DOI: 10.1007/s00702-020-02175-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
26 van Poppelen D, Sisodia V, de Haan RJ, Dijkgraaf MGW, Schuurman PR, Geurtsen GJ, Berk AEM, de Bie RMA, Dijk JM. Protocol of a randomized open label multicentre trial comparing continuous intrajejunal levodopa infusion with deep brain stimulation in Parkinson's disease - the INfusion VErsus STimulation (INVEST) study. BMC Neurol 2020;20:40. [PMID: 32005175 DOI: 10.1186/s12883-020-1621-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
27 Hoy SM. Levodopa/Carbidopa Enteral Suspension: A Review in Advanced Parkinson’s Disease. Drugs 2019;79:1709-18. [DOI: 10.1007/s40265-019-01201-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]